期刊文献+

不同手术方式联合早期膀胱灌注化疗对浅表性膀胱癌患者生活质量的影响 被引量:21

Comparison of quality of life in superficial bladder cancer patients receiving different surgical procedures and immediate instillation of chemotherapy
下载PDF
导出
摘要 目的探讨不同手术方式联合早期膀胱灌注化疗对浅表性膀胱癌患者生活质量的影响。方法将60例浅表性膀胱癌患者随机分为治疗组和对照组各30例。治疗组采用经尿道汽化电切术,对照组采用膀胱部分切除术,两组患者术后均接受早期吡柔比星膀胱灌注化疗,记录患者一般情况、手术情况、术后3年复发情况及生活质量并进行比较分析。结果治疗组在手术时间、出血量、留置导尿时间、住院时间方面均优于对照组,两组比较差异有统计学意义。治疗组术后3年复发率17.2%、首次复发时间(30.2±5.3)个月,优于对照组复发率17.9%及首次复发时间(25.4±8.6)个月,组间比较差异无统计学意义。治疗组患者在生理健康、心理健康、独立性三方面的术后得分明显优于对照组,差异有统计学意义(P<0.05)。结论经尿道汽化电切术可明显提高浅表性膀胱癌患者的生活质量,同时减轻患者的手术创伤及痛苦,延缓肿瘤复发时间。 Objective To observe the postoperative quality of life in patients with superficial bladder cancer receiving different surgical procedures and immediate instillation of chemotherapy.Methods 60 cases of superficial bladder cancer patients were collected and divided into two groups randomly,the observe group and the control group.Patients of the observe group received transurethral electrovaporization of bladder tumor,while the control group received partial cystectomy.All patients received immediate instillation of chemotherapy with pirarubicin.General informations,operation data,recurrence rates and quality of life improvement were compared between the two groups.Results The duration of operation,amount of bleeding,indwelling catheter and hospital stay of the observe group was better than the control group,the difference was statistically significant.The 3-year recurrence rate of observe group was 17.2% compared to 17.9% of the control group,and the recurrence time was(30.2±5.3) months and(25.4±8.6) months respectively,the difference was not statistically significant.The physiological part,mental health and independence of the observe group was better than the control group,the difference was statistically significant.Conclusion Transurethral electrovaporization of bladder tumor can improve the quality of life of patients with superficial bladder cancer and delay recurrence time of tumors with minimal invasion and pain.
出处 《四川医学》 CAS 2013年第6期763-765,共3页 Sichuan Medical Journal
关键词 浅表性膀胱癌 经尿道汽化电切术 膀胱部分切除术 生活质量 superficial bladder cancer transurethral electrovaporization of bladder tumor partial cystectomy quality of life
  • 相关文献

参考文献8

二级参考文献48

共引文献91

同被引文献129

  • 1孙鹏.《膀胱癌诊断治疗指南》解读——非肌层浸润性膀胱癌的治疗[J].泌尿外科杂志(电子版),2009(1):51-53. 被引量:4
  • 2姚剑.表阿霉素黏膜下浸润注射加单次灌注预防浅表性膀胱癌术后复发的研究[J].中华泌尿外科杂志,2004,25(10):679-681. 被引量:6
  • 3ARAKAWA M, NAKAMURA K, YAMADA Y, et al. Intravesical administration of pirarubicin against superficial bladder cancer: Relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect[J]. Exp Ther Med, 2011, 2(5): 901-905.
  • 4XYLINAS E, SHARIAT SF. Words of wisdom: Re: Prospective randomized phase II trial of a single early intravesical instillation ofpirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upperurinary tract urothelial carcinoma: the THP Monotherapy Study Group trial [J]. Eur Urol, 2013, 64 (4): 683-684.
  • 5NAGASHIMA M, ARAKI A, YANAGISAWA M, et al. Effect of prophylactic intravesical instillation of pirarubicin to prevent re- current bladder tumors following nephrouretereetomy for upper urinary tract cancer[J]. Hinyokika Kiyo, 2013, 59(4): 213-216.
  • 6BHATTACHARYA A, LI Y, SHI Y, et al. Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination [J]. Carcinogenesis, 2013, 34(11): 2593-2599.
  • 7ARAKAWA M, NAKAMURA K, YAMADA Y, et al. Intravesical administration of pirarubicin against superficial bladder cancer:. relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect [J]. Exp Ther Med, 2011, 2 (5): 901-905.
  • 8LIU W, CAO Y, FERN?NDEZ MI, et al. Additive antitumoral effect of interleukin-12 gene therapy and chemotherapy in the treatment of urothelial bladder cancer in vitro and in vivo[J]. Int Urol Nephrol, 2011, 43(3): 721-727.
  • 9MARUYAMA T, HIGUCHI Y, SUZUKI T, et al. Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells[J]. J Infect Chemother, 2011, 17 (1): 11-16.
  • 10Arakawa M, Nakamura K, Yamada Y, et al. Intravesical administration of pirarubicin against superficial bladder cancer: relation- ship between tumor tissue concentration and exposure time in the bladder or thera- peutic effect[J]. Experimental and therape-utic medicine, 2011, 2(5): 901-905.

引证文献21

二级引证文献132

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部